Australian company Eurogold to acquire Bard1AG

EUROGOLD Ltd has entered into binding share sale and purchase agreements under which it has agreed to acquire all of the issued shares in the capital of BARD1AG S.A. In addition to the BARD1AG Acquisition, Eurogold proposes to undertake a capital raising under a prospectus to raise up to approximately $3,000,000. The BARD1AG Acquisition and the Public Offer (both separately and together) will involve a significant change in the nature and scale of the Company's activities which requires the approval of shareholders. After the acquisition the company want to fulfil the requirements for re-quotation of its shares on the Official List of the Australian exchange ASX.

Eurogold has agreed to acquire 100% of the shares on issue in BARD1AG on the following terms: Cash consideration of CHF 291,600 to 9 vendors; and 206,598,903 fully paid ordinary Eurogold shares and 206,598,903 Eurogold 'performance shares' to 5 vendors.

About BARD1AG
Founded in 2011 by Dr Irmgard Irminger-Finger, the head of the Molecular Gynecology and Obstetrics Laboratory at the University Hospital of Geneva (UHG) and the world's leading BARD1 biology researcher, BARD1AG has pioneered, through the development of certain proprietary intellectual property, a simple blood test for screening and diagnosing lung cancer at early stages of disease progression (the 'BARD1AG Lung Cancer Test').